



Living Cell Technologies Limited

Company Announcement

LCT extends SPP closing date until 17 December 2009

11 December 2009: Sydney, Australia, Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) To allow shareholders the opportunity to review their entitlement following the recent developments, LCT has decided to extend the Share Purchase Plan closing date by 4 business days from 11 December to Thursday 17 December 2009.

The Chairman Dr David Brookes said, "The relevance of LCT's platform technologies has been highlighted by the lifting of the Australian moratorium on xenotransplantation yesterday. The rationale for the re-emerging interest in xenotransplantation has followed balanced discussion and careful decision making at international (WHO) and national levels (NHMRC Australia; Medsafe NZ). LCT is uniquely placed with an established and accredited GMP facility for cell therapies, and a pathogen (virus or any other contaminant) free source of pig cells.

Patient safety is always paramount and LCT is comfortable with a leadership role in innovative replacement therapies for chronic medical disorders. Simple and safe delivery of required pure cells via protective coating has been a key approach to ensuring patient well-being.

This is an exciting phase in the company's history with the potential to carry out clinical trials in Australia, where many investors and the majority of directors reside, rewarding years of belief by our shareholders."

-Ends-

For further information: www.lctglobal.com

Dr. Paul Tan
Chief Executive Officer
Mob: +6421 608 784 (NZ)
Tel: +64 9 276 2690
ptan@lctglobal.com

Prof. Bob Elliott
Medical Director
Mob: +64 27 292 4177
Tel: +64 9 276 2690
belliott@lctglobal.com

Mr John Cowan
Finance & Administration Manager
Tel: +64 9 276 2690
jcowan@lctglobal.com

Paul Dekkers
Investor and Media Relations
Tel: +612 9237 2800
pdekkers@bcg.com.au

About Living Cell Technologies: www.lctglobal.com

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The Company entered clinical trials for its diabetes product in 2007. For the treatment of Parkinson's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. LCT's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection.



LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.